Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of BH011 in Subjects With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer After Bacillus Calmette-Guérin

NCT06732531 is registered in ClinicalTrials.gov with Zhuhai Beihai Biotech Co., Ltd as lead sponsor.

NCT NCT06732531
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06732531 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of BH011 in Subjects With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer After Bacillus Calmette-Guérin
Lead sponsor
Zhuhai Beihai Biotech Co., Ltd
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 3, 2022
Completion date
December 31, 2025
Enrollment
48 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, non muscle invasive